Literature DB >> 7011999

Effects of route and time of administration of antiserum on protection of mice from lethal infection due to group B Streptococcus type III.

B F Stanton, R S Baltimore, D G Shedd.   

Abstract

The present study examines a mouse model of infection due to group B Streptococcus serotype III (GBS-III) as to the route and timing of antiserum administration for protection and quantitation of bacteremia with and without antiserum. Data for these parameters are contrasted with those after challenge with serotype Ia of group B Streptococcus (GBS-Ia). An intraperitoneal injection of GBS organisms and protective antiserum from a single syringe can be used to create an animal model of disease. Intraperitoneal injection of GBS-III resulted in bacteremia at 0.5 h both in animals who did not receive antiserum (17.4 X 10(2) +/- 7.6 X 10(2) colony-forming units per ml of blood samples) and in animals who received antiserum (19.3 X 10(1) +/- 6.8 X 10(1) colony-forming units per ml). Although intraperitoneal injection of GBS-Ia also resulted in bacteremia evident by 0.5 h in unprotected animals (30.1 X 10(2) +/- 3.8 X 10(2) colony-forming units per ml), no bacteremia occurred in protected recipients of this organism. Bacteremia due to GBS-Ia and GBS-III logarithmically increased until at least 7 h. Bacteremia due to GBS-III in protected animals was cleared by 24 h. Protection against GBS disease did not require simultaneous or proximate administration of the organism and the antiserum. Mice could be protected from death after intraperitoneal challenge with GBS-III or GBS-Ia by antiserum administered intravenously or intraperitoneally from 6 h before to 2.5 h after challenge.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011999      PMCID: PMC351796          DOI: 10.1128/iai.31.1.391-395.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Experimental group B streptococcal infections in mice: hematogenous virulence and mucosal colonization.

Authors:  D Furtado
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

2.  Transmission of group B streptococci among parturient women and their neonates.

Authors:  C J Baker; F F Barrett
Journal:  J Pediatr       Date:  1973-12       Impact factor: 4.406

3.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

Review 4.  Summary of the workshop on perinatal infections due to group B Streptococcus.

Authors: 
Journal:  J Infect Dis       Date:  1977-07       Impact factor: 5.226

5.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

6.  Opsonin system of the group B streptococcus.

Authors:  J H Mathews; P H Klesius; R A Zimmerman
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

7.  Immunity to the group B streptococci: interaction of serum and macrophages with types Ia, Ib, and Ic.

Authors:  B F Anthony
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

8.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

9.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.

Authors:  R C Lancefield; M McCarty; W N Everly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  4 in total

1.  Experimental model of type IV Streptococcus agalactiae (group B streptococcus) infection in mice with early development of septic arthritis.

Authors:  L Tissi; P Marconi; P Mosci; L Merletti; P Cornacchione; E Rosati; S Recchia; C von Hunolstein; G Orefici
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

2.  Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci).

Authors:  C von Hunolstein; S D'Ascenzi; B Wagner; J Jelínková; G Alfarone; S Recchia; M Wagner; G Orefici
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

3.  Mouse protection assay for group B streptococcus type III.

Authors:  D O Fleming
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

4.  Acute infection of mice with highly virulent group B streptococci as a host resistance model for immunotoxicity assessment.

Authors:  D B Barnes; J M Hardin; S B Pruett
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.